普罗布考在治疗原发性高胆固醇血症中的效用。
Usefulness of probucol in treating primary hypercholesterolemia.
作者信息
Enjalbert M, Lussier-Cacan S, DuBreuil-Quidoz S, LeLorier J, Davignon J
出版信息
Can Med Assoc J. 1980 Oct 18;123(8):754-7.
Probucol (1 g per day) was administered in a double-blind crossover trial to 16 patients with familial hypercholesterolemia who had previously been tested for their response to clofibrate. Probucol led to a fall in the plasma cholesterol concentration of 15% or more (mean 20.2%) in 5 of the 12 clofibrate-resistant patients and between 8% and 15% in 3 others. The reduction was statistically significant in 7 of these 12 patients as well as in 3 of the 4 patients sensitive to clofibrate. Thus, probucol has a place in the treatment of patients with primary hypercholesterolemia who do not respond to clofibrate.
在一项双盲交叉试验中，对16名家族性高胆固醇血症患者给予普罗布考（每日1克），这些患者之前已接受过氯贝丁酯反应测试。在12名对氯贝丁酯耐药的患者中，有5名患者的血浆胆固醇浓度下降了15%或更多（平均为20.2%），另外3名患者的血浆胆固醇浓度下降了8%至15%。在这12名患者中有7名以及在4名对氯贝丁酯敏感的患者中有3名，这种降低具有统计学意义。因此，普罗布考在治疗对氯贝丁酯无反应的原发性高胆固醇血症患者中占有一席之地。
Zotero 插件